Seelos Therapeutics, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2023-03-03: Study NCT05332678; Company role Lead sponsor; Phase Phase 2; Status Withdrawn.
- 2022-06-03: Study NCT05490563; Company role Lead sponsor; Phase Phase 2, Phase 3; Status Terminated.
- 2022-02-21: Study NCT05136885; Company role Collaborator; Phase Phase 2, Phase 3; Status Completed.
- 2020-12-17: Study NCT04669665; Company role Lead sponsor; Phase Phase 2; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2023-03-03 | NCT05332678 SLS-005 (Trehalose Injection) in the Treatment of Alzheimer's Disease | Lead sponsor | Phase 2 | Withdrawn | Alzheimer's Disease | 0 | 2023-04-10 |
| 2022-06-03 | NCT05490563 STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia | Lead sponsor | Phase 2, Phase 3 | Terminated | Spinocerebellar Ataxia Type 3 | 23 | 2023-11-24 |
| 2022-02-21 | NCT05136885 HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose | Collaborator Lead: Merit E. Cudkowicz, MD | Phase 2, Phase 3 | Completed Results posted | Amyotrophic Lateral Sclerosis | 161 | 2023-08-25 |
| 2020-12-17 | NCT04669665 A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide | Lead sponsor | Phase 2 | Completed | Depressive Disorder, Major; Suicidal | 164 | 2023-07-14 |
| NCT05597436 Intermediate-Sized Expanded Access Study | Lead sponsor | Expanded_access | No longer available | Amyotrophic Lateral Sclerosis |